Corporate Members

Bristol Myers Squibb

About Us: At Bristol Myers Squibb, we work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.  We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms. We are pursuing therapies at the forefront of scientific discovery with the goal of bringing an exciting new generation of life-changing treatments to patients. We aspire to be at the center of a vibrant healthcare innovation ecosystem, where academic research centers, biotech and biopharma companies all contribute to continued scientific advancement.  During this unprecedented time, if you have U.S. patients who have lost jobs and health insurance due to COVID-19, we will o­ffer our covered medicines at no cost. For a complete list of our covered medicines, patients can call 1-800-721-8909 or visit www.bms.com to learn more.

Website:
www.bms.com

Representative Contacts: 
Patrick Curtin, Patrick.Curtin@bms.com, 908-420-7093

Daiichi-Sankyo

About us: The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.

Website: www.DSCancerEnterprise.com ; www.dsi.com

Representative Contact:
Dan Pagana, dpagana@dsi.com, 570-974-1860

Social Media:
Twitter: https://twitter.com/DaiichiSankyoUS
LinkedIn: https://www.linkedin.com/company/daiichi-sankyo/

Immunomedics

About Us: Immunomedics is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers.

Website: https://www.immunomedics.com/

Representatives:
Rep contact:
Stephen Gardner, Oncology Account Manager: Sgardner@immunomedics.com 412 2160075

Director of National Accounts:
Nicole Cornett: NCornett@immunomedics.com 2013414605 

Merck

Social Media:
LinkedIn: linkedin.com/company/Merck
Facebook: www.facebook.com/Merckinvents
Twitter: twitter.com/Merck
Instagram: instagram.com/Merck
YouTube: youtube.com/user/Merck

Oncopeptides

About us: Oncopeptides was established solely to develop therapies for difficult-to-treat hematological diseases, and we are committed to bringing patients the treatments they need and the hope they deserve.

Websites: 
https://www.oncopeptides.com/en
https://www.pepaxtohcp.com/

Representatives:

Sharon Maffei, Oncology Account Manager
Sharon.maffei@oncopeptides.com
570-357-6627

Nancy Ramos, Oncology Account Manager
Nancy.ramos@oncopeptides.com
917-494-4631

Seagen Inc.

About Us: Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.

Click here to learn more.

Website: www.seagen.com; https://www.seagen.com/medicines

5k Members

Aveo

About Us: AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. AVEO’s strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to do the same in other geographies. In March 2021, AVEO received FDA approval of FOTIVDA® (tivozanib). To learn more about FOTIVDA efficacy, safety, and relevant resources, visit our website at FOTIVDAHCP.com or click the link below.

Website: https://www.aveooncology.com

Representative:

Jenny Passett – Oncology Account Manager

(716) 713-6708

jpassett@aveooncology.com

Aveo Oncology – 30 Winter Street, Boston, MA 02108

Social Media:

Twitter: https://twitter.com/aveooncology

LinkedIn: https://www.linkedin.com/company/54167?trk=tyah

Astellas Pharma

About us: Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical conducting business in more than 70 countries around the world. Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

Website: https://www.astellas.com/us

Representatives:

Eric Lapham, Senior Access and Reimbursement Manager, Health Systems

Cell/Mobile: 732 245 4232

Eric.Lapham@astellas.com

Social Media:

Twitter at @AstellasUS

Facebook at www.facebook.com/AstellasUS

LinkedIn at www.linkedin.com/company/astellas-pharma-us.

Exelixis, Inc., 

About us: Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. To ensure you have the latest clinical data, including links to our pivotal trial publications, and important product information, visit our website.

Website: https://www.exelixis.com

Representative:

Michael Nozzi
Senior Oncology Account Manager
570-357-1906
mnozzi@exelixis.com

Natera

About us: Natera is a pioneer and global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, cancer researchers, biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn. 

Website: www.natera.com/oncology

Representatives:

Mike Weber, Clinical Oncology Specialist, Greater Philadelphia: mweber@natera.com (215) 630-6505

Jonathan Liess, Clinical Oncology Specialist, Greater Allentown: jliess@natera.com (215) 279-1033

Cynthia Los, Clinical Oncology Specialist, Southeastern PA, DE & MD: clos@natera.com (443) 622-7072

Lydia Hammond, Clinical Oncology Specialist, Greater Harrisburg: lhammond@natera.com (507) 261-9537

Tiffany Stein, Clinical Oncology Specialist, Greater Pittsburgh: tstein@natera.com (412) 980-0763

Social Media:
Facebook: https://www.facebook.com/NateraGenetics/
Twitter: https://twitter.com/NateraOncology
LinkedIn: https://www.linkedin.com/company/natera
YouTube: https://www.youtube.com/watch?v=NnmuCPnr9vM

Pfizer Oncology

Representatives:

Sue Sproat, CPC, CHONC, CMR, Field Reimbursement Manager - MD, DC, DE, PA
410-627-0807 (cell) | 484-323-7995 (fax)
susan.r.sproat@pfizer.com